Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Arvinas

Arvinas
2013 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
ARVN STOCK SYMBOL
1 INVESTMENTS
$38.87 SHARE PRICE (As of Monday Closing)
Description

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 5 Science Park
  • 395 Winchester Avenue
  • New Haven, CT 06511
  • United States

+1 (203) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Arvinas’s full profile, request a free trial.

Arvinas Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$10.19 - $39.95 $1.52B $38.42 -$2.06 365K 39M

Arvinas Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 572,048 643,278
Revenue 41,523 14,324 7,579 6,669
EBITDA (68,074) (43,187) (23,853) (14,362)
Net Income (65,332) (41,480) (24,049) (14,351)
Total Assets 209,094 199,282 66,848 37,937
Total Debt 4,365 2,154 310 454
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Arvinas Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Arvinas‘s full profile, request access.

Request full access to PitchBook

Arvinas Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Arvinas‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Arvinas Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rigontec Formerly VC-backed Munich, Germany 000.00 000000&0 000.00
000000 0000 Formerly VC-backed Jerusalem, Israel 00 00000 00000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
0000000 Venture Capital-Backed Cambridge, MA 000 00000000000 000
0000000 0000000000 Venture Capital-Backed Diepenbeek, Belgium 0 000.00 00000000000 000.00
To view this company’s complete list of competitors, request access »

Arvinas Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000 0000000 04-Jun-2019 00000 0000000 Biotechnology 0000 0000000 00.0
To view this company’s complete investment and acquisition history, request access »

Arvinas Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Arvinas‘s full profile, request access.

Request full access to PitchBook

Arvinas Executive Team (15)

Name Title Board
Seat
Contact
Info
John Houston Ph.D Chief Executive Officer & Board Member
Sean Cassidy Chief Financial Officer & Chief Accounting Officer
Ian Taylor Ph.D Chief Scientific Officer
Craig Crews Ph.D Founder & Chief Scientific Advisor
Daniel Von Hoff MD Scientific Advisor

6 Former Executives

You’re viewing 5 of 15 executives. Get the full list »

Arvinas Board Members (14)

Name Representing Role Since Contact
Info
Bradley Margus Self Board Member 000 0000
Briggs Morrison MD Self Board Member 000 0000
Edward Kennedy Jr. Self Board Member 000 0000
Jakob Loven Ph.D Nextech Invest Board Member 000 0000
John Houston Ph.D Arvinas Chief Executive Officer & Board Member 000 0000

4 Former Board Members

You’re viewing 5 of 14 board members. Get the full list »